Navigation Links
1st SynCardia Total Artificial Heart Patient Discharged from Ankara University in Turkey
Date:9/20/2012

TUCSON, Ariz., Sept. 20, 2012 /PRNewswire/ -- SynCardia Systems, Inc. (www.syncardia.com), manufacturer of the world's first and only FDA, Health Canada and CE (Europe) approved Total Artificial Heart, announced today that the first patient to receive the SynCardia temporary Total Artificial Heart at Ankara University Heart Center in Turkey has been discharged from the hospital. The patient, 47-year-old Arif Sahin, is currently waiting for a matching donor heart with his family using the Freedom® portable driver to power his SynCardia Total Artificial Heart.

(Photo: http://photos.prnewswire.com/prnh/20120920/LA77951)

In 2011, Mr. Sahin suffered a severe heart attack that perforated one of his heart ventricles and caused extensive tissue damage. He underwent coronary bypass surgery at a local hospital, but during a follow-up visit several months later, an echocardiogram revealed he had a blood clot attached to his ventricle wall as well as a pseudoaneurysm.

After suffering from two strokes as a result of thromboembolism, Mr. Sahin was admitted to Ankara University Heart Center. When doctors took him into the operating room on May 7, the goal of surgery was to remove the clot and repair the pseudoaneurysm, but the SynCardia Total Artificial Heart was readied on stand-by just in case.

"An intra-operative examination revealed the extent of the cardiac damage to be inoperable and the size of the clot was overwhelming," said Prof. Dr. A. Ruchan Akar, Director of the Heart Transplant Program at Ankara University. "Although we were prepared for every possible scenario, once we opened his chest, it became clear that biventricular replacement with the SynCardia Total Artificial Heart was our only option to save this patient."

On July 10, Mr. Sahin became the second Total Artificial Heart patient in Turkey to be discharged from the hospital using the Freedom portable driver. The first patient, Omer Bayrak from Istanbul, has been enjoying life at home with the Freedom portable driver for more than a year.

"I am glad to say that we were able to help this patient," said Prof. Dr. Akar. "I'd like to thank my team for their excellent work and our surgical proctor, Dr. Latif Arusoglu, for his guidance. We now have a comprehensive mechanical circulatory support program thanks to the SynCardia Total Artificial Heart, which is the only solution for some of our patients."

Weighing approximately 6 kg (13.5 pounds), the Freedom portable driver is the world's first wearable power supply for the SynCardia Total Artificial Heart. The Freedom driver is CE approved for use in Europe and undergoing an FDA-approved Investigational Device Exemption (IDE) clinical study in the U.S.

SynCardia recognizes and thanks Ufuk Yaranli and Natura Medikal Urunler Ltd., the Turkish distributor for the Total Artificial Heart, for their commitment and ongoing support of the four SynCardia Certified Centers in Turkey and the additional four Turkish hospitals currently undergoing the certification process.

CAUTION – The Freedom portable driver is an investigational device, limited by United States law to investigational use.

About the SynCardia temporary Total Artificial Heart

SynCardia Systems, Inc. (Tucson, AZ) is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE approved Total Artificial Heart. Originally used as a permanent replacement heart, SynCardia's Total Artificial Heart is currently approved as a bridge to transplant for people dying from end-stage biventricular heart failure. There have been more than 1,000 implants of the Total Artificial Heart, accounting for more than 270 patient years of life.

Similar to a heart transplant, SynCardia's Total Artificial Heart replaces both failing heart ventricles and the four heart valves, eliminating the symptoms and source of end-stage biventricular failure. Unlike a donor heart, the Total Artificial Heart is immediately available at SynCardia Certified Centers. It is the only device that provides immediate, safe blood flow of up to 9.5 liters per minute through each ventricle. This high volume of safe blood flow helps speed the recovery of vital organs, helping make the patient a better transplant candidate.

SynCardia Wins Two Gold Stevies® at 2012 American Business Awards

On June 18, 2012, SynCardia was honored with two Gold Stevie® Awards at the 10th Annual American Business Awards. SynCardia won "Company of the Year – Health Products and Services" and "Most Innovative Company of the Year – up to 100 Employees." See the full list of SynCardia Awards & Recognition, which includes accolades from Forbes, Fast Company and more.


'/>"/>
SOURCE SynCardia Systems, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. SynCardia Total Artificial Heart Patient Featured in U.S. News & World Reports "Best Hospitals" Issue
2. EJK Duisburg Becomes One of the Most Active SynCardia Certified Centers in Europe
3. SynCardias Record-Setting Q2 Marks 5th Consecutive Profitable Quarter
4. 50% of U.S. News & World Reports "Best Hospitals" for Cardiology & Heart Surgery Making the SynCardia Total Artificial Heart Part of Their Toolbox
5. 1st SynCardia Total Artificial Heart Implant Performed in New England
6. 3 Pediatric Centers that Offer SynCardia Total Artificial Heart Named in Top 10 for "Best Childrens Hospitals"
7. SynCardia Posts Record Revenue and Profit in Q1 2012
8. Solos Endoscopy Posts Total Assets of $2,426,883 for Period Ended June 30, 2012
9. Met-Pro Corporations Strobic Air Business Unit Receives New Equipment Orders Totaling Approximately $1.5 Million
10. Introducing DenMats Totally New Web Site @ DenMat.com Featuring a New On-Line Store, New Page Design & Special On-Line Savings
11. Total Therapeutic Management, Inc. invites directors of quality improvement to learn secrets of provider engagement strategies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- Research and Markets has announced the ... (United States, China, Japan, Brazil, United Kingdom, Germany, France, ... Surgical Procedure Volumes: ... provides surgical procedure volume data in a geographic context. ... analysis of growth drivers and inhibitors, including world population ...
(Date:6/23/2016)... , June 23, 2016 ... but it continues to present great opportunities to investors. ... for today: Intrexon Corp. (NYSE: XON ), ... Pharmaceuticals Inc. (NASDAQ: ARNA ), and Regeneron ... about these stocks and receive your complimentary trade alerts ...
(Date:6/23/2016)... SAN DIEGO , June 23, 2016 /PRNewswire/ ... advancing programs that address medical conditions resulting from ... that it has appointed Greg Doyle ... member of Leading BioSciences, executive management team and ... officer and chief financial officer. He will provide ...
Breaking Medicine Technology:
(Date:6/26/2016)... Carolina (PRWEB) , ... June 26, 2016 , ... ... of a new product that was developed to enhance the health of felines. The ... centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American ... Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. ... including advance care planning, healthcare costs and patient and family engagement. , AIR ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand ... project," said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s ... within Final Cut Pro X . Simply select a ProHand generator and drag ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... A ... procedures that most people are unfamiliar with. The article goes on to state that ... but also many of these less common operations such as calf and cheek reduction. ...
Breaking Medicine News(10 mins):